Arbutus Biopharma Corp (ABUS) - Net Assets
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has net assets worth $76.58 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.62 Million) and total liabilities ($18.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash flow conversion of Arbutus Biopharma Corp to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $76.58 Million |
| % of Total Assets | 80.93% |
| Annual Growth Rate | 6.38% |
| 5-Year Change | -54.81% |
| 10-Year Change | -62.28% |
| Growth Volatility | 2291.47 |
Arbutus Biopharma Corp - Net Assets Trend (1998–2025)
This chart illustrates how Arbutus Biopharma Corp's net assets have evolved over time, based on quarterly financial data. Explore Arbutus Biopharma Corp strategic investment ratio to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Arbutus Biopharma Corp (1998–2025)
The table below shows the annual net assets of Arbutus Biopharma Corp from 1998 to 2025. For live valuation and market cap data, see Arbutus Biopharma Corp market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $76.58 Million | -21.35% |
| 2024-12-31 | $97.37 Million | -8.16% |
| 2023-12-31 | $106.02 Million | -22.53% |
| 2022-12-31 | $136.85 Million | -19.23% |
| 2021-12-31 | $169.44 Million | +66.17% |
| 2020-12-31 | $101.97 Million | +40.17% |
| 2019-12-31 | $72.74 Million | -63.67% |
| 2018-12-31 | $200.23 Million | +9.72% |
| 2017-12-31 | $182.50 Million | -10.10% |
| 2016-12-31 | $203.00 Million | -62.93% |
| 2015-12-31 | $547.68 Million | +522.36% |
| 2014-12-31 | $88.00 Million | +48.67% |
| 2013-12-31 | $59.19 Million | +44.65% |
| 2012-12-31 | $40.92 Million | +686.08% |
| 2011-12-31 | $5.21 Million | -51.49% |
| 2010-12-31 | $10.73 Million | -69.72% |
| 2009-12-31 | $35.44 Million | -7.45% |
| 2008-12-31 | $38.29 Million | +108.43% |
| 2007-12-31 | $18.37 Million | +11711.55% |
| 2006-12-31 | $155.53K | +100.84% |
| 2005-12-31 | $-18.49 Million | -76.18% |
| 2004-12-31 | $-10.50 Million | -124.20% |
| 2003-12-31 | $43.38 Million | -4.34% |
| 2002-12-31 | $45.35 Million | -26.25% |
| 2001-12-31 | $61.49 Million | +104.76% |
| 2000-12-31 | $30.03 Million | +11.72% |
| 1999-12-31 | $26.88 Million | +86.28% |
| 1998-12-31 | $14.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arbutus Biopharma Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 135952588035.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.42 Billion | 1856.23% |
| Other Comprehensive Income | $-48.10 Million | -62.81% |
| Other Components | $83.32 Million | 108.80% |
| Total Equity | $76.58 Million | 100.00% |
Arbutus Biopharma Corp Competitors by Market Cap
The table below lists competitors of Arbutus Biopharma Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
$854.74 Million |
|
Guangdong Greenway Technology Co Ltd
SHG:688345
|
$854.93 Million |
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
$855.27 Million |
|
Sichuan Jiuyuan Yinhai Software Co Ltd
SHE:002777
|
$855.43 Million |
|
Indus Holding AG
XETRA:INH
|
$854.67 Million |
|
Huarong Chemical Co. Ltd.
SHE:301256
|
$854.11 Million |
|
Jilin Forest
SHG:600189
|
$853.99 Million |
|
E2E Networks Limited
NSE:E2E
|
$853.66 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arbutus Biopharma Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 97,366,000 to 76,576,000, a change of -20,790,000 (-21.4%).
- Net loss of 33,501,000 reduced equity.
- Other comprehensive income increased equity by 37,000.
- Other factors increased equity by 12,674,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.50 Million | -43.75% |
| Other Comprehensive Income | $37.00K | +0.05% |
| Other Changes | $12.67 Million | +16.55% |
| Total Change | $- | -21.35% |
Book Value vs Market Value Analysis
This analysis compares Arbutus Biopharma Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.70x to 11.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $6.67 | $4.64 | x |
| 1999-12-31 | $9.54 | $4.64 | x |
| 2000-12-31 | $6.09 | $4.64 | x |
| 2001-12-31 | $12.13 | $4.64 | x |
| 2002-12-31 | $6.90 | $4.64 | x |
| 2003-12-31 | $6.09 | $4.64 | x |
| 2004-12-31 | $-1.36 | $4.64 | x |
| 2005-12-31 | $-2.40 | $4.64 | x |
| 2006-12-31 | $0.04 | $4.64 | x |
| 2007-12-31 | $3.85 | $4.64 | x |
| 2008-12-31 | $4.72 | $4.64 | x |
| 2009-12-31 | $3.43 | $4.64 | x |
| 2010-12-31 | $1.04 | $4.64 | x |
| 2011-12-31 | $0.46 | $4.64 | x |
| 2012-12-31 | $2.86 | $4.64 | x |
| 2013-12-31 | $3.87 | $4.64 | x |
| 2014-12-31 | $3.92 | $4.64 | x |
| 2015-12-31 | $12.05 | $4.64 | x |
| 2016-12-31 | $3.83 | $4.64 | x |
| 2017-12-31 | $3.33 | $4.64 | x |
| 2018-12-31 | $3.62 | $4.64 | x |
| 2019-12-31 | $1.27 | $4.64 | x |
| 2020-12-31 | $1.34 | $4.64 | x |
| 2021-12-31 | $1.59 | $4.64 | x |
| 2022-12-31 | $0.91 | $4.64 | x |
| 2023-12-31 | $0.64 | $4.64 | x |
| 2024-12-31 | $0.52 | $4.64 | x |
| 2025-12-31 | $0.40 | $4.64 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arbutus Biopharma Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -43.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -237.88%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.24x
- Recent ROE (-43.75%) is below the historical average (362.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -60.67% | -713.22% | 0.08x | 1.10x | $-10.20 Million |
| 1999 | -30.41% | -716.68% | 0.04x | 1.07x | $-10.86 Million |
| 2000 | -30.65% | -520.56% | 0.05x | 1.08x | $-12.21 Million |
| 2001 | -22.79% | -405.13% | 0.05x | 1.10x | $-20.16 Million |
| 2002 | -59.09% | -528.27% | 0.10x | 1.17x | $-31.33 Million |
| 2003 | -78.55% | -1247.26% | 0.05x | 1.17x | $-38.41 Million |
| 2004 | 0.00% | -230.49% | 0.30x | 0.00x | $-27.00 Million |
| 2005 | 0.00% | -60.64% | 0.72x | 0.00x | $-6.21 Million |
| 2006 | 11625.33% | 132.90% | 2.25x | 38.80x | $18.06 Million |
| 2007 | -14.06% | -16.22% | 0.64x | 1.35x | $-4.42 Million |
| 2008 | -30.60% | -121.56% | 0.23x | 1.11x | $-15.55 Million |
| 2009 | -26.32% | -67.68% | 0.33x | 1.18x | $-12.87 Million |
| 2010 | -115.68% | -58.14% | 1.02x | 1.96x | $-13.49 Million |
| 2011 | -186.95% | -59.69% | 1.19x | 2.63x | $-10.25 Million |
| 2012 | 73.18% | 211.19% | 0.27x | 1.29x | $25.86 Million |
| 2013 | -23.76% | -90.95% | 0.22x | 1.21x | $-19.98 Million |
| 2014 | -44.09% | -258.67% | 0.13x | 1.34x | $-47.60 Million |
| 2015 | -11.16% | -245.73% | 0.03x | 1.30x | $-115.89 Million |
| 2016 | -189.21% | -25606.67% | 0.01x | 1.36x | $-404.40 Million |
| 2017 | -46.25% | -788.79% | 0.05x | 1.30x | $-102.65 Million |
| 2018 | -28.52% | -967.80% | 0.03x | 1.14x | $-77.12 Million |
| 2019 | -211.32% | -2557.36% | 0.06x | 1.45x | $-161.00 Million |
| 2020 | -62.52% | -921.97% | 0.05x | 1.34x | $-73.94 Million |
| 2021 | -45.00% | -693.91% | 0.05x | 1.21x | $-93.19 Million |
| 2022 | -50.75% | -178.01% | 0.20x | 1.43x | $-83.14 Million |
| 2023 | -68.71% | -401.57% | 0.13x | 1.36x | $-83.45 Million |
| 2024 | -71.81% | -1133.04% | 0.05x | 1.35x | $-79.66 Million |
| 2025 | -43.75% | -237.88% | 0.15x | 1.24x | $-41.16 Million |
Industry Comparison
This section compares Arbutus Biopharma Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,863,964
- Average return on equity (ROE) among peers: -43.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $76.58 Million | -60.67% | 0.24x | $854.72 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $86.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $42.37 Million | -200.47% | 0.88x | $323.66 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $183.46 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $804.47 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-52.67 Million | 0.00% | 0.00x | $3.63 Billion |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and A… Read more